Co-Authors
This is a "connection" page, showing publications co-authored by AUNG NAING and MOUHAMMED A HABRA.
Connection Strength
2.288
-
Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1).
Score: 0.740
-
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer. 2019 09 18; 7(1):253.
Score: 0.717
-
Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience. J Clin Endocrinol Metab. 2022 04 19; 107(5):1239-1246.
Score: 0.214
-
Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas. Cancers (Basel). 2020 Aug 16; 12(8).
Score: 0.191
-
Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. Cancer Chemother Pharmacol. 2016 07; 78(1):167-71.
Score: 0.143
-
Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol. 2013 Dec; 169(6):891-899.
Score: 0.119
-
Metformin: an old drug with new potential. Expert Opin Investig Drugs. 2013 Dec; 22(12):1511-7.
Score: 0.118
-
A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma. Invest New Drugs. 2020 10; 38(5):1421-1429.
Score: 0.046